CANCER RESEARCH TECHNOLOGY LIMITED

1. CANCER RESEARCH TECHNOLOGY LIMITED 2002-10-01 → present
2. CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED 1988-04-06 → 2002-10-01
3. CARLTON MEDICAL PRODUCTS LIMITED 1982-07-05 → 1988-04-06
4. RESTROSE LIMITED 1982-03-31 → 1982-07-05

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors believe that the company has adequate resources to continue as a going concern for at least 12 months from the authorisation of the financial statements. Cancer Research UK is committed to the success and sustainability of the Company and has provided this support as it aligns with Cancer Research UK's primary purpose of developing new diagnostics and treatments which will result in cancer patient benefits. On 1 April 2025, the company obtained a grant from Cancer Research UK to fund its patient benefit activities in the financial year ending 31 March 2026 and a further commitment of funding to 31 March 2026, subject to the terms of the funding agreement. During the current year Cancer Research UK formally waived its right to £6.3m of Gift Aid that it was entitled to in respect of taxable profits relating to the year to 31 March 2024.”

Group structure

1. CANCER RESEARCH TECHNOLOGY LIMITED · parent
   1. Cancer Research Ventures Limited 100% · England & Wales · dormant
   2. Cancer Research Horizons Limited 100% · England & Wales · dormant
   3. Cancer Research Scotland Institute Limited 100% · Scotland · dormant
   4. Cancer Research UK Scotland Institute Limited 100% · Scotland · dormant
   5. Cancer Research Technology Inc. 100% · USA · provide a service to its parent company by marketing the company's projects. A secondary activity is to widen the company's intellectual property sourcing in the United States of America and increase business development.

Significant events

• “Since April 2022, CRT began trading as Cancer Research Horizons, to reflect the company's profile in the life sciences sector and its ambitions to increase further its translational capabilities and output.”
• “Royalty income in the year from abiraterone acetate continues to reduce due to expiry of the European patent in September 2022. Olaparib royalty income fell following the expiry of royalty rights in Europe and Rest of the World in November 2024.”
• “Royalty income from Capivasertib of £3,211k (2024: £708k) grew during the year following the successful launch of the drug in December 2023.”
• “CRT has had a successful year across a range of activities, including the continued pursuit of drug discovery research with industrial partners, entering 63 revenue bearing/future revenue generating agreements and investing in 8 new portfolio companies (2024: 48 commercial deals and 6 new portfolio companies). During the year, the CancerTools.org business established its own fully operational laboratory, enabling in-house manufacturing of research reagents.”
• “On 1 April 2025, the company obtained a grant from Cancer Research UK to fund its patient benefit activities in the financial year ending 31 March 2026 and a further commitment of funding to 31 March 2026, subject to the terms of the funding agreement.”
• “During the current year Cancer Research UK formally waived its right to £6.3m of Gift Aid that it was entitled to in respect of taxable profits relating to the year to 31 March 2024.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -28.3%

  £55,157,000 → £39,533,000

• Cash

  -31.6%

  £2,359,000 → £1,613,000

• Net assets

  -32.7%

  £23,902,000 → £16,078,000

• Employees

  +5.7%

  281 → 297

• Operating profit

  -166.1%

  £9,293,000 → -£6,146,000

• Profit before tax

  -205.1%

  £7,319,000 → -£7,694,000

• Wages

  +10.3%

  £13,909,000 → £15,346,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers